etapidi is a proven and effective type of infusion treatment known as immunotherapy
etapidi is a cancer treatment containing the active substance tislelizumab. It is a monoclonal antibody, a type of protein specifically designed to recognize and bind to a particular target in the body known as the programmed death-1 (PD-1) receptor. This receptor is found on the surface of T cells and B cells—types of white blood cells that are part of the body’s immune system and natural defense.
When PD-1 is activated by cancer cells, it can suppress the activity of T cells. By blocking PD-1, etapidi prevents this suppression, thereby enabling T cells to remain active and helping the immune system fight cancer.
What is an infusion?
An infusion is the delivery of a treatment directly into your bloodstream through a vein. This is called an intravenous (IV) infusion.
It is a very common treatment method for people with various health challenges. You may receive your ETAPIDI infusions at your doctor’s office, an infusion center, or another healthcare location
What is immunotherapy?
Immunotherapy is a type of treatment that is designed to work with your own immune system to find and destroy cancer cells. It helps boost your immune cells, such as T cells,* to attack growing cancer cells.
It is a different type of treatment than chemotherapy, which can rapidly target growing cells in the body. Often, immunotherapy and chemotherapy treatments can be partnered together to give your body the extra help it needs.
*T cells, or T lymphocytes, are a type of white blood cell
How It Works?
etapidi is designed to work with T cells in your immune system
In a healthy immune system, T cells are “switched on.”
The T cells are active, traveling through your body, looking for and eliminating disease and infection.
In the immune system of someone with cancer, many T cells are “switched off.”
Cancer can “flip a switch” to turn off T cells, preventing them from finding and eliminating the cancer cells.
In the immune system of someone receiving etapidi treatment, T cells are “switched back on” to fight cancer.
etapidi attaches to T cells, keeping the “switch” on, so T cells can find and eliminate the cancer cells.
etapdi has been shown to work in people who have tested positive for the PD-L1 biomarker. Levels of PD-L1 vary from person to person. If you are receiving etapidi, your doctor likely has found that certain cells in your tumor show PD-L1.